Hematologic Toxicity Patterns In Patients Treated With Chemoradiation For Anal Squamous Cell Carcinoma

Abstract

CRT followed by total mesorectal excision (TME). 60 patients in the consolidation chemotherapy group received two cycles XELOX between CRT and TME, while 84 patients in the standard treatment group without consolidation chemotherapy. Two groups were matched according to age, gender, TNM staging, and ECOG grade. The pCR (ypT0N0), tumor downstaging (ypT0-2N0) after TME and adverse events (AEs) during and post treatment were compared between the treatment groups using multivariable logistic regression analysis. Results: The consolidation chemotherapy group improved pCR rate (19.3% versus 4.9%, p Z 0.01) and tumor downstaging rate (45.8% versus 24.6%, p Z 0.009) compared to the standard treatment group. After adjustment for clinical tumor stage, clinical nodal stage and time interval to surgery, patients with consolidation chemotherapy were more likely to reach pCR (adjusted odds ratio 4.91, 95%CI 1.01-23.79, p Z 0.048). adverse events (AEs) during and post treatment in the two groups were 54.1% versus 49.3% (p Z 0.57), respectively. In addition, the incidence of any grade 1-2 AEs in the two groups was 93.4% versus 95.1% (p Z 0.93), while the incidence of grade 3 adverse events was 1.6% versus 2.4% (p Z 0.74), respectively. No grade 4 AEs were occurred in two groups Conclusion: Adding neoadjuvant consolidation chemotherapy after CRT significantly improved the pCR rate without increasing during and post treatment in patients with LARC.